Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 40

1.

Seeking the state of the art in standardized measurement of health care resource use and costs in juvenile idiopathic arthritis: a scoping review.

Kip MMA, Currie G, Marshall DA, Grazziotin Lago L, Twilt M, Vastert SJ, Swart JF, Wulffraat N, Yeung RSM, Benseler SM, IJzerman MJ; UCAN CAN-DU Health Economics Working Group.

Pediatr Rheumatol Online J. 2019 May 6;17(1):20. doi: 10.1186/s12969-019-0321-x. Review.

2.

Molecular signature characterisation of different inflammatory phenotypes of systemic juvenile idiopathic arthritis.

Gohar F, McArdle A, Jones M, Callan N, Hernandez B, Kessel C, Miranda-Garcia M, Lavric M, Holzinger D, Pretzer C, Lainka E, Vastert SJ, de Roock S, FitzGerald O, Pennington SR, Foell D.

Ann Rheum Dis. 2019 Aug;78(8):1107-1113. doi: 10.1136/annrheumdis-2019-215051. Epub 2019 Apr 20.

PMID:
31005900
3.

Treatment to Target Using Recombinant Interleukin-1 Receptor Antagonist as First-Line Monotherapy in New-Onset Systemic Juvenile Idiopathic Arthritis: Results From a Five-Year Follow-Up Study.

Ter Haar NM, van Dijkhuizen EHP, Swart JF, van Royen-Kerkhof A, El Idrissi A, Leek AP, de Jager W, de Groot MCH, Haitjema S, Holzinger D, Foell D, van Loosdregt J, Wulffraat NM, de Roock S, Vastert SJ.

Arthritis Rheumatol. 2019 Jul;71(7):1163-1173. doi: 10.1002/art.40865. Epub 2019 May 25.

4.

Consensus-based recommendations for the management of juvenile localised scleroderma.

Zulian F, Culpo R, Sperotto F, Anton J, Avcin T, Baildam EM, Boros C, Chaitow J, Constantin T, Kasapcopur O, Knupp Feitosa de Oliveira S, Pilkington CA, Russo R, Toplak N, van Royen A, Saad Magalhães C, Vastert SJ, Wulffraat NM, Foeldvari I.

Ann Rheum Dis. 2019 Aug;78(8):1019-1024. doi: 10.1136/annrheumdis-2018-214697. Epub 2019 Mar 2.

5.

Restoring T Cell Tolerance, Exploring the Potential of Histone Deacetylase Inhibitors for the Treatment of Juvenile Idiopathic Arthritis.

Nijhuis L, Peeters JGC, Vastert SJ, van Loosdregt J.

Front Immunol. 2019 Feb 7;10:151. doi: 10.3389/fimmu.2019.00151. eCollection 2019. Review.

6.

Juvenile Arthritis Patients Suffering from Chronic Inflammation Have Increased Activity of Both IDO and GTP-CH1 Pathways But Decreased BH4 Efficacy: Implications for Well-Being, Including Fatigue, Cognitive Impairment, Anxiety, and Depression.

Korte-Bouws GAH, Albers E, Voskamp M, Hendriksen H, de Leeuw LR, Güntürkün O, de Roock S, Vastert SJ, Korte SM.

Pharmaceuticals (Basel). 2019 Jan 8;12(1). pii: E9. doi: 10.3390/ph12010009.

7.

Microbiome Analytics of the Gut Microbiota in Patients With Juvenile Idiopathic Arthritis: A Longitudinal Observational Cohort Study.

van Dijkhuizen EHP, Del Chierico F, Malattia C, Russo A, Pires Marafon D, Ter Haar NM, Magni-Manzoni S, Vastert SJ, Dallapiccola B, Prakken B, Martini A, De Benedetti F, Putignani L; Model Driven Paediatric European Digital Repository Consortium.

Arthritis Rheumatol. 2019 Jun;71(6):1000-1010. doi: 10.1002/art.40827. Epub 2019 Apr 29.

8.

Dutch juvenile idiopathic arthritis patients, carers and clinicians create a research agenda together following the James Lind Alliance method: a study protocol.

Schoemaker CG, Armbrust W, Swart JF, Vastert SJ, van Loosdregt J, Verwoerd A, Whiting C, Cowan K, Olsder W, Versluis E, van Vliet R, Fernhout MJ, Bookelman SL, Cappon J, van den Berg JM, Schatorjé E, Muller PCEH, Kamphuis S, de Boer J, Lelieveld OTHM, van der Net J, Jongsma KR, van Rensen A, Dedding C, Wulffraat NM.

Pediatr Rheumatol Online J. 2018 Sep 15;16(1):57. doi: 10.1186/s12969-018-0276-3. Review.

9.

Prediction of inactive disease in juvenile idiopathic arthritis: a multicentre observational cohort study.

van Dijkhuizen EHP, Aidonopoulos O, Ter Haar NM, Pires Marafon D, Magni-Manzoni S, Ioannidis YE, Putignani L, Vastert SJ, Malattia C, De Benedetti F, Martini A.

Rheumatology (Oxford). 2018 Oct 1;57(10):1752-1760. doi: 10.1093/rheumatology/key148.

PMID:
29931340
10.

Treating juvenile idiopathic arthritis to target: recommendations of an international task force.

Ravelli A, Consolaro A, Horneff G, Laxer RM, Lovell DJ, Wulffraat NM, Akikusa JD, Al-Mayouf SM, Antón J, Avcin T, Berard RA, Beresford MW, Burgos-Vargas R, Cimaz R, De Benedetti F, Demirkaya E, Foell D, Itoh Y, Lahdenne P, Morgan EM, Quartier P, Ruperto N, Russo R, Saad-Magalhães C, Sawhney S, Scott C, Shenoi S, Swart JF, Uziel Y, Vastert SJ, Smolen JS.

Ann Rheum Dis. 2018 Jun;77(6):819-828. doi: 10.1136/annrheumdis-2018-213030. Epub 2018 Apr 11.

PMID:
29643108
11.

Editorial: Toward Personalized Treatment for Systemic Juvenile Idiopathic Arthritis.

Vastert SJ, Nigrovic PA.

Arthritis Rheumatol. 2018 Aug;70(8):1172-1174. doi: 10.1002/art.40501. Epub 2018 Jun 29. No abstract available.

12.

The safety of live-attenuated vaccines in patients using IL-1 or IL-6 blockade: an international survey.

Jeyaratnam J, Ter Haar NM, Lachmann HJ, Kasapcopur O, Ombrello AK, Rigante D, Dedeoglu F, Baris EH, Vastert SJ, Wulffraat NM, Frenkel J.

Pediatr Rheumatol Online J. 2018 Mar 21;16(1):19. doi: 10.1186/s12969-018-0235-z.

13.

Contradictory and weak evidence on the effectiveness of anti-emetics for MTX-intolerance in JIA-patients.

Schoemaker CG, van Dijkhuizen EHP, Vastert SJ.

Pediatr Rheumatol Online J. 2018 Feb 15;16(1):13. doi: 10.1186/s12969-018-0229-x. No abstract available.

14.

Reversal of Sepsis-Like Features of Neutrophils by Interleukin-1 Blockade in Patients With Systemic-Onset Juvenile Idiopathic Arthritis.

Ter Haar NM, Tak T, Mokry M, Scholman RC, Meerding JM, de Jager W, Verwoerd A, Foell D, Vogl T, Roth J, Leliefeld PHC, van Loosdregt J, Koenderman L, Vastert SJ, de Roock S.

Arthritis Rheumatol. 2018 Jun;70(6):943-956. doi: 10.1002/art.40442. Epub 2018 May 7.

15.

Patient's experiences with the care for juvenile idiopathic arthritis across Europe.

van Dijkhuizen EHP, Egert T, Egert Y, Costello W, Schoemaker C, Fernhout M, Kepic M, Martini A, Scala S, Rotstein-Grein I, Vastert SJ, Wulffraat NM.

Pediatr Rheumatol Online J. 2018 Feb 8;16(1):10. doi: 10.1186/s12969-018-0226-0.

16.

Recommendations for collaborative paediatric research including biobanking in Europe: a Single Hub and Access point for paediatric Rheumatology in Europe (SHARE) initiative.

Kuemmerle-Deschner JB, Hansmann S, Wulffraat NM, Vastert SJ, Hens K, Anton J, Avcin T, Martini A, Koné-Paut I, Uziel Y, Ravelli A, Wouters C, Shaw D, Özen S, Eikelberg A, Prakken BJ, Ruperto N, Horneff G, Constantin T, Beresford MW, Sikken M, Foster HE, Haug I, Schuller S, Jägle C, Benseler SM.

Ann Rheum Dis. 2018 Mar;77(3):319-327. doi: 10.1136/annrheumdis-2017-211904. Epub 2017 Oct 11. Review.

PMID:
29021237
17.

Review: Enhancers in Autoimmune Arthritis: Implications and Therapeutic Potential.

Peeters JGC, Vastert SJ, van Wijk F, van Loosdregt J.

Arthritis Rheumatol. 2017 Oct;69(10):1925-1936. doi: 10.1002/art.40194. Review. No abstract available.

18.

European evidence-based recommendations for diagnosis and treatment of paediatric antiphospholipid syndrome: the SHARE initiative.

Groot N, de Graeff N, Avcin T, Bader-Meunier B, Dolezalova P, Feldman B, Kenet G, Koné-Paut I, Lahdenne P, Marks SD, McCann L, Pilkington CA, Ravelli A, van Royen-Kerkhof A, Uziel Y, Vastert SJ, Wulffraat NM, Ozen S, Brogan P, Kamphuis S, Beresford MW.

Ann Rheum Dis. 2017 Oct;76(10):1637-1641. doi: 10.1136/annrheumdis-2016-211001. Epub 2017 May 4. Review.

PMID:
28473426
19.

The human microbiome and juvenile idiopathic arthritis.

Verwoerd A, Ter Haar NM, de Roock S, Vastert SJ, Bogaert D.

Pediatr Rheumatol Online J. 2016 Sep 20;14(1):55. doi: 10.1186/s12969-016-0114-4. Review.

20.

Autoimmune disease-associated gene expression is reduced by BET-inhibition.

Peeters JG, Vervoort SJ, Mijnheer G, de Roock S, Vastert SJ, Nieuwenhuis EE, van Wijk F, Prakken BJ, Mokry M, van Loosdregt J.

Genom Data. 2015 Nov 7;7:14-7. doi: 10.1016/j.gdata.2015.11.004. eCollection 2016 Mar.

Supplemental Content

Loading ...
Support Center